Karunakaran P. Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India.
2. Herman SE, Gordon AL, Hertlein E, et al. Bruton’s tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287–96.
3. Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid. 2013;8:37–45.
4. Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6:59.
5. Bhatt V, Alejandro L, Michael A, et al. The promising impact of ibrutinib, a Bruton’s tyrosine kinase inhibitor, for the management of lymphoid malignancies. Pharmacotherapy. 2014;34:303–14.
6. Uppala V, Tabassum A, Lavanya K, Neerja V, Sharma JVC. Method development and validation of ibrutinib by RP-HPLC in bulk and pharmaceutical dosage form. World J Pharm Pharm Sci. 2016;5(5):868–74.
7. Tomlinson MG, Kurosaki T, Berson AE, Fujii GH, Johnston JA, Bolen JB. Reconstitution of Btk signaling by the atypical Tec family tyrosine kinases Bmx and Txk. J Biol Chem. 1999;274:13577–85.
8. Mehra S, Nicholls M, Taylor J, Poggi A. The evolving role of Bruton’s tyrosine kinase inhibitors in B cell lymphomas. Int J Mol Sci. 2024;25(14):7516. doi:10.3390/ijms25147516.
9. Treon S. How I treat Waldenstrom macroglobulinemia. Blood. 2015;126:721–32.
10. Castillo J, Olszewski A, Kanan S, Meid K, Hunter Z, Treon S. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015;169:81–9.
11. Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–45.
12. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med. 2015;372(15):1430–40.
13. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.
14. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37.
15. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15(10):1090–9.
16. Jaglowski SM, Jones JA, Nagar V, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126(7):842–50.
17. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (HELIOS): a randomized, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200–11.
18. Brown JR, Barrientos JC, Barr PM, et al. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015;125(19):2915–22.
19. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810–7.
20. Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, et al. BTK drives ibrutinib resistance via ERK1/2 and protects BTK MYD88-mutated cells by a paracrine mechanism.
21. Byrd JC, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, Coutre S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133:2031–42. doi:10.1182/blood-2018-08-870238.
22. Stühlinger MC, Weltermann A, Staber P, Heintel D, Nösslinger T, Steurer M. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. Wien Klin Wochenschr. 2020;132(3-4):97–109. doi:10.1007/s00508-019-1534-1.
23. de Jong J, Sukbuntherng J, Skee D, Murphy J, O'Brien S, Byrd JC. Evaluation of the pharmacokinetics and food effect of oral ibrutinib in healthy subjects and chronic lymphocytic leukemia patients. Blood. 2014 Oct;128(22):4637.
24. Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, et al. Absorption, metabolism, and excretion of oral 14C-radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015;43(2):289–97.
25. Solimando DA Jr, Waddell JA. Drug monographs: ibrutinib and ramucirumab. Hosp Pharm. 2014;49(8):702–9.
26. ChemicalBook. Ibrutinib: Uses, Mechanism of Action and Side Effects. 2024.
27. FDA. IMBRUVICA (ibrutinib) capsules, tablets, or suspension, for oral use. Approved August 2022.
28. EMA. Imbruvica (ibrutinib) oral capsules or tablets.
29. Health Canada. IMBRUVICA (ibrutinib) oral capsules or tablets.
30. Pharmacyclics, Janssen Biotech. Imbruvica (ibrutinib) capsules/tablets [prescribing information]. Sunnyvale, CA; Horsham, PA; February 2018.
31. Shakeel F, Iqbal M, Ezzeldin E, Haq N. Thermodynamics of solubility of ibrutinib in ethanol + water cosolvent mixtures at different temperatures. J Mol Liq. 2015;211:375–80. doi:10.1016/j.molliq.2015.06.016.
32. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. Biopharmaceutics classification system: scientific basis for biowaiver extensions. Pharm Res. 2002;19(7):921–5.
33. Trunov D, Ižovský J, Beranek J. Characterization of amorphous ibrutinib thermal stability. 2025 Jan 7.
34. Wei L, Su YK, Lin CM. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (BTK) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. Oncotarget. 2016;7(43):71345–58. doi:10.18632/oncotarget.11572.
35. Blood. Abstract 4170. 2016;128(22). doi:10.1182/blood.V128.22.4170.4170.
36. Muqbil I, Chaker M, Aboukameel A, Mohammad RM. Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model. Heliyon. 2019;5(8):e02290. doi:10.1016/j.heliyon.2019.e02290.
37. Chu Y, Lee S, Shah T, Yin C, Barth M. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma model. OncoImmunology. 2018;7(10):e1512455. doi:10.1080/2162402X.2018.1512455.
38. The New England Journal of Medicine. Ibrutinib: Mechanisms of Action and Clinical Applications in Hematologic Malignancies.